Released Nov 8, 2021, after the close
10-Q filed Nov 9, 2021, 40 days after period end · 0001162194-21-000087
Q3 2021 · 10-Q
Revenue$28.50M$28.50M −28.5% vs Q3 2020−8.1% vs Q2 2021
Net Income-$13.84M-$13.84M N/M vs Q3 2020N/M vs Q2 2021
EPS Diluted-$0.18-$0.18 N/M vs Q3 2020N/M vs Q2 2021
Operating Income-$19,612,000N/M
Operating Cash Flowderived-$9,494,000N/M
Free Cash Flowderived-$11,200,000N/M
Margins · derived
Operating margin-68.8%−55.1 pt vs Q3 2020
Net margin-48.6%−33.5 pt vs Q3 2020
What the release said
The release
Same quarter
| Metric | Q3 2021 | Q3 2020 | Q3 2019 | Q3 2018 |
|---|---|---|---|---|
| Revenue | $28.50M | $39.86M | $26.50M | $28.96M |
| Net Income | -$13.84M | -$6.00M | -$12.89M | -$14.75M |
| EPS Diluted | -$0.18 | -$0.08 | -$0.19 | -$0.38 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR